medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 4

<< Back Next >>

Med Int Mex 2020; 36 (4)

Sulodexide decreases albuminuria in patients with diabetic nephropathy

Frati-Munari AC

Language: Spanish
References: 53
Page: 530-542
PDF size: 238.95 Kb.


ABSTRACT

Clinical and experimental evidences with sulodexide (SLDX) treatment in diabetic nephropathy were reviewed. Patients with type 1 or 2 diabetes and micro or macroalbuminuria in 15 observational (n = 658) and 17 controlled (n = 3473) studies were included. SLDX by parenteral and/or oral route was used during 2 weeks to one year. A decrease of micro or macroalbuminuria was noticed in all the studies performed with the original SLDX, while 3 controlled studies using a different SLDX did not show any change. Some controlled investigations suggested that SLDX efficacy is dose- and length-dependent. Several studies showed a sustained beneficial effect lasting up to 4 months after discontinuation of SLDX. Two meta-analysis concluded that SLDX is effective to diminish albumin excretion rate in diabetic nephropathy with similar adverse effects to control groups. Five experiments in diabetic animals showed histological improvement, mainly in renal glomerulus. One experimental study performed with a nonoriginal SLDX did not show any change. It is concluded that sulodexide is useful as an add on treatment of diabetic nephropathy with micro or macroalbuminuria.


REFERENCES

  1. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27 (suppl 1): s79-s83. doi. org/10.2337/diacare.27.2007.S79

  2. Méndez-Durán A, Méndez-Bueno JF, Tapia-Yáñez T, Muñoz-Montes A, Aguilar-Sánchez L. Epidemiología de la insuficiencia renal en México. Dialisis Transpl 2010; 31: 7-11. DOI: 10.1016/S1886-2845(10)70004-7

  3. De Zeew D, Ramuzzi G, Parving HH. Proteinuria a target for renoprotection in patients with type 2 diabetic nephropathy. Lessons from RENAAL. Kidney Int 2004; 65: 2309-20. doi: 10.1111 / j.1523-1755.2004.00653.x

  4. Ramuzzi G, Benigni A, Ramuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-96. DOI: 10.1172 / JCI27699

  5. Fioretto P, Steffes MV, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75. DOI: 10.1056/NEJM199807093390202

  6. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017; 40 (suppl 1): S1-S135.

  7. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailay G, Favis N et al. Effectiveness of sensor-augmented insulinpump therapy in type 1 diabetes. N Engl J Med 2010; 363: 311-20. doi: 10.1056/NEJMoa1002853

  8. Lewis EJ, Hunsicker LG, Bain RP, Rhode RD. The effect of angiotensin-converting-enzyme inhibition in diabetic nephropathy. N Engl J Med 1993; 329: 1456-62. doi: 10.1056/ NEJM199311113292004

  9. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Lewis JB, Ritz E et al. Renoprotective effect of the angiotensin receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60. DOI: 10.1056/NEJMoa011303

  10. Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide. Int Angiol 2014; 33: 229-35.

  11. Gambaro G, Skrha J, Ceriello A. Glycosaminoglycan therapy for long-term complications? Diabetologia 1998; 41: 975- 79. DOI: 10.1007/s001250051016

  12. Broekhuisen LN, Mooij HL, Kastelein JJ, Stroes ES, Vink H, Nieuwdorp M. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. Curr Opin Lipidol 2009; 20: 57-62. doi: 10.1097/ MOL.0b013e328321b587

  13. Frati-Munari AC. Importancia médica del glucocáliz endotelial. Parte 2. Su papel en enfermedades vasculares y complicaciones de la diabetes mellitus. Arch Cardiol Mex 2014; 84: 110-16. doi.org/10.1016/j. acmx.2013.10.006

  14. Solini A, Carraro A, Barzon I, Crepaldi G. Therapy with glycosaminoglycans lower albumin excretion rate in non-insulin dependent diabetic patients with macroalbuminuria. Diab Nutr Metab 1994; 7: 304-7.

  15. Skrha J, Perusicova J, Pont’uch P, Oksa A. Glycosaminoglycan sulodexide decreases albuminuria in diabetic patients. Diab Res Clin Pract 1997; 38: 25-31. doi: 10.1016/s0168- 8227(97)00076-4

  16. Szelachowska M, Poplawska A, Topolska J, Grimaldi M. A pilot study on the effect of the glycosaminoglycan sulodexide on microalbuminuria in type I diabetic patients. Curr Med Res Opin 1997; 13: 539-45. DOI: 10.1185/03007999709113327

  17. Perusicova J, Skrha J. Effect of glycosaminoglycan sulodexide on albuminuria in diabetic patients. Vnitr Lek 1997; 748-52.

  18. Poplawska A, Szelachowska M, Topolska J, Wysocka-Solowie B, Kinalska I. Effect of glycosaminoglycans on urinary albumin excretion in insulin-dependent diabetic patients with micro- or macroalbuminuria. Diab Res Clin Pract 1997; 38: 109-14. doi: 10.1016/s0168-8227(97)00096-x

  19. Shestakova MV, Chugunova A, Vorontsov AV, Dedov II. Efficacy of sulodexide, low molecular heparin, in therapy of diabetic nephropathy. Ter Ark 1997; 69: 34-7. PMID: 9297270

  20. Zalevskaya AG, Astamirova KhS, Karpova IA, Popova SG. A trial of the use of the low-molecular heparin sulodexide in the therapy of diabetic nephropathy. Ter Ark 1998; 70: 71-4.

  21. Razovskii BA, Tarasov AV, Trel’skaia NIu et al. Sulodexide in the treatment of diabetic nephropathy. Klin Med (Mosk) 1998; 76: 40-2.

  22. Meizhen S, Linhua T, Jiamin C. Clinical study on type II diabetic nephropathy treated with sulodexide. Chin New Drugs J 1999; 8: 408-10.

  23. Oksa A, Pontuch P, Kratochvilova H. Effect of glycosaminoglycan sulodexide on albuminuria in patients with diabetes mellitus. Bratisl Lek Listy 1999; 100: 486-89.

  24. Peterkova VA, Mishina II, Sherbacheva LN. Sulodexide in the treatment of diabetic nephropathy in children. Diabetes (Mosk)1999; (3): 31-33.

  25. Arcangeli A, Pedone T, Crescenti C, Ianni L. Microalbuminuria e diabete tipo 2: efficacia clinica del sulodexide. Dati preliminari. Minerva Cardioangiol 2000; 48 (suppl 2 al N.11): 72-3.

  26. Lichiardopol R, Ionescu-Tirgoviste C, Serban V, Dumitrescu C, Mota M, Ghise G, et al. Eftul sulodexidului asupra eliminarii urinare de albumina la un grup de pacienti cu diabet zaharat. J Rom Diabet Ntr Bol Metabol 2001; 2: 28-31.

  27. Trusov VV, Yeremunskuna NG. Prolonged therapy of diabetic nephropathy with sulodexide. Prob Endocrinol 2004; 50: 11-6.

  28. Blouza S, Dakhli S, Abid H, Aissaoui M, Ardhaoui I, Abdallah NB et al. Efficacy of low-dose sulodexide in the management of diabetic nephropathy. J Nephrol 2010; 23: 415-24.

  29. Velussi M, Cernigoi AM, Dapas F, De Monte A. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diab Nutr Metab 1966; 9: 53-8.

  30. Solini A, Ricci F, Vergnani L, Crepaldi G. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care 1997; 20: 819-23. DOI: 10.2337/diacare.20.5.819

  31. Dedov I, Shestakova M, Vorontzov A, Palazzini E. A randomized controlled study of sulodexide therapy for the treatment of diabetic nephropathy. Nephrol Dial Transplant 1997; 12: 2295-2300. DOI: 10.1093/ndt/12.11.2295

  32. Gambaro G, Kinalska I, Oksa A, Pont’uch P, Hertlová M, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-25. DOI: 10.1097/01.asn.0000014254.87188.e5

  33. Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005; 18: 568-74.

  34. Sulkikowska B, Olejnicza KH, Muszynska M, Odrowaz- Sypniewzka G, Gaddi A et al. Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients. Am J Nephrol 2006; 26: 621-8. DOI: 10.1159/000098195

  35. Chen S, Wei M, Gao Y, Hu Y, Xiong Y, Zhang S et al. A randomized controlled trial of sulodexide for early diabetic nephropathy. Chin J Evidence-Based Med 2008; 8: 162-6.

  36. Heerspink HL, Greene T, Lewis JB, Raz I, Thode RD, Hunsicker LG et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008; 23: 1946-54. doi: 10.1093/ndt/gfm893

  37. Hu M, Lu B, Meng Y, Zhou J, Xu X, Xiao X. Therapeutic effects of sulodexide combined with irbesartan on elderly patients with diabetic nephropathy. Pract Geriatr 2009; 23: 276-8.

  38. Wang T, Wang Z, Yang F. Clinical observation of sulodexide in treatment of type 2 diabetes with early nephropathy. Med Pharmaceut World 2009; 11: 769-71.

  39. Ren J, Su J, Huang C. Effect of sulodexide on microalbuminuria of the third stage of type 2 diabetic nephropathy. Modern Med J China (MMJC) 2010; 12: 31-33.

  40. Lewis EJ, Lewis JB, Green T, Hunsicker LG, Berl T, Pohl MA et al. Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized trial. Am J Kidney Dis 2001; 58: 729-36. DOI: 10.1053/j.ajkd.2011.06.020

  41. Zhang H, Kang P, Li J, Du J, Sun W, Xie C, et al. Study of the effect of Chulo on albuminuria in diabetic nephropathy. Med J Integr Traditional Chin & West Med 2011; 20: 405-6, 416.

  42. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012; 23: 123-130. DOI: 10.1681/ASN.2011040378

  43. Chen L, Yang R. Effect of sulodexide on urine protein excretion in type 2 diabetes with proteinuria. Med J Wuhan Univ 2013; 34: 450-2, 456.

  44. Xiong Y. Treatment of sulodexide on albuminuria in early diabetic nephropathy. J Jiangham Univ (Nat Sci Ed) 2014; 42: 90-92.

  45. Dakhli S, Kheldher A, Borni Z, Achour A, Hachicha J. A clinical experience on sulodexide in the treatment of patients with diabetic nephropathy. J Nephrol Ther 2016; 7: 1-9. doi:10.4172/2161-0959.1000284

  46. Li R, Xing J, Mu X, Wang H, Zhang L, Zhao Y et al. Sulodexide therapy for treatment of diabetic nephropathy, a metaanalysis and literature review. Drug Res Dev Ther 2015; 9: 6275-83. doi: 10.2147/DDDT.S87973

  47. Shang HX, Zhao JY, Shen X, Cai T, Zhang DM, Dong JJ, Liao L. The efficacy and safety of sulodexide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2016; 9: 12481-91.

  48. Gambaro G, Cavazzana AO, Luzzi P, Piccoli A, Borsatti A, Crepaldi G et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285-91. DOI: 10.1038/ki.1992.288

  49. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S et al. Treatment with glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46: 797-806. doi: 10.1038/ki.1994.335

  50. Ceol M, Nerlich A, Baggio B, Anglani E, Sauer U, Schleicher E, Gambaro G. Increased glomerular Alpha 1 (IV) collagen expression and deposition in long-term diabetic rats is prevented by chronic glycosaminoglycan treatment. Lab Invest 1996; 74: 484-95.

  51. Yung S, Chau MKM, Zhang Q, Zhang CZ, Chan TK. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocin-induced type I diabetic nephropathy. PLOS ONE 2013; 8 (e54501): 1-19. doi: 10.1371/journal.pone.0054501

  52. Cha JJ, Kang YS, Hyun YY, Han SY, Jee YH, Han KH et al. Sulodexide improves renal function through reduction of vascular endotelial growth factor in type 2 diabetic rats. Life Sci 2013; 82: 1118-24. doi: 10.1016/j.lfs.2013.04.008

  53. Rossini M, Naito T, Yang H, Freeman M, Donnen E, Ma LJ, et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant 2010; 25: 1803-10. doi: 10.1093/ndt/gfp724




2020     |     www.medigraphic.com